International – Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death

Positive high-level results from the TACKLE phase 3 COVID-19 treatment trial showed AstraZeneca's AZD7442, a long-acting antibody (LAAB) combination, achieved a statistically significant reduction in severe COVID-19 or death compared to placebo in non-hospitalised patients with mild-to-moderate symptomatic COVID-19.

A total of 90% of participants enrolled were from populations at high risk of severe COVID-19, including those with co-morbidities.

The trial met the primary endpoint, with a dose of 600mg of AZD7442 given by intramuscular injection reducing the risk of developing severe COVID-19 or death (from any cause) by 50% compared to placebo in outpatients who have had symptoms for seven days or less. In the trial, out of 407 participants receiving AZD7442, there were 18 events. Out of the 415 participants receiving placebo in the trial, there were 37 events…